Close Menu

NEW YORK (GenomeWeb) – Fluidigm today announced the pricing of an underwritten public offering of 8,150,000 shares of its common stock at a price of $6.75 per share, for aggregate gross proceeds of about $55 million.

In addition, Fluidigm has granted underwriters of the offering a 30-day option to purchase up to 1,222,500 additional shares of common stock at the public offering price.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A South African university has told the Wellcome Sanger Institute to return DNA samples it has from indigenous African communities, The Times reports.

The University of California, Berkeley's Rasmus Nielsen and Xinzhu Wei have retracted their CCR5 gene paper due to a technical artifact.

 

University of Virginia researchers are exploring a genetic risk test to gauge type 1 diabetes risk, NPR reports.

In PNAS this week: researchers compare two high-grade neuroendocrine lung cancers, height among ancient Europeans, and more.